Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

Advanced Solid Tumors or Lymphomas Clinical Trial

Official title:
A Real-World Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

Status Recruiting

Clinical Trial Summary

The NHWD-870 Phase I clinical trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with advanced tumors. The objectives of this retrospective study were to preliminarily evaluate the anti-tumor efficacy of NHWD-870 HCl in patients with advanced solid tumors or lymphomas and to preliminarily evaluate biomarkers associated with the efficacy of NHWD-870 HCl in the treatment of patients with advanced solid tumors or lymphomas, to provide a basis for identifying the enriched population for the late-stage trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Solid Tumors or Lymphomas
Lymphoma

Clinical Trial Details

NCT number	NCT06073938
Study type	Observational
Source	Hunan Province Tumor Hospital
Contact	Yongchang Zhang, MD
Phone	+8613873123436
Email	zhangyongchang@csu.edu.cn
Status	Recruiting
Phase
Start date	September 20, 2022
Completion date	June 30, 2024

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02812875` - A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas	Phase 1
	Recruiting	`NCT05374226` - A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas	Phase 1